TH 302: all 23 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate CancerNot yet recruitingNCT06836726Phase 2
- A Study of Evofosfamide in Combination with Zalifrelimab and BalstilimabRecruitingNCT06782555Phase 1/2
- A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic TumoursCompletedNCT02402062Phase 2Results posted
- TH-302 in Combination With Bevacizumab for GlioblastomaCompletedNCT02342379Phase 2Results posted
- A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue SarcomaTerminatedNCT02255110Phase 2Results posted
- Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic CancerTerminatedNCT02047500Phase 1Results posted
- A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced MelanomaTerminatedNCT01864538Phase 2Results posted
- Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic AdenocarcinomaCompletedNCT01746979Phase 3Results posted
- Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following BevacizumabCompletedNCT01403610Phase 2Results posted
- Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic AdenocarcinomaCompletedNCT01144455Phase 2Results posted
- Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue SarcomaCompletedNCT00742963Phase 1/2Results posted
- Immunotherapy Study of Evofosfamide in Combination With IpilimumabStatus unknownNCT03098160Phase 1
- Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.WithdrawnNCT02598687Phase 1
- Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract CancerCompletedNCT02433639Phase 2
- A Phase 1 TH-302 Mass Balance TrialCompletedNCT02076230Phase 1
- A Cardiac Safety Study of TH-302 in Patients With Advanced Solid TumorsStatus unknownNCT02020226Phase 1
- Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple MyelomaStatus unknownNCT01522872Phase 1/2
- Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT01497444Phase 1
- Dose Escalation Study of Pazopanib Plus TH-302CompletedNCT01485042Phase 1
- Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine TumorsStatus unknownNCT01381822Phase 1
- Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced LeukemiasCompletedNCT01149915Phase 1
- Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid TumorsCompletedNCT00743379Phase 1/2
- A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid TumorsCompletedNCT00495144Phase 1